871555-75-8

Basic information

• Product Name: Carbamic acid,N-[4-chloro-3-(teifluoromethyl)phenyl]-,phenyl ester
• Synonyms: Carbamic acid,N-[4-chloro-3-(teifluoromethyl)phenyl]-,phenyl ester;phenyl 4-chloro-3-(trifluoromethyl)phenylcarbamate
• CAS NO: 871555-75-8
• Molecular Formula: C₁₄H₉ClF₃NO₂
• Molecular Weight: 315.6749696
• Mol File: 871555-75-8.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Carbamic acid,N-[4-chloro-3-(teifluoromethyl)phenyl]-,phenyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid,N-[4-chloro-3-(teifluoromethyl)phenyl]-,phenyl ester(871555-75-8)
• EPA Substance Registry System: Carbamic acid,N-[4-chloro-3-(teifluoromethyl)phenyl]-,phenyl ester(871555-75-8)

Safety Data

• Hazardous Substances Data: 871555-75-8(Hazardous Substances Data)

Usage

General Description

"Carbamic acid, N-[4-chloro-3-(trifluoromethyl)phenyl]-, phenyl ester is a chemical compound primarily used in the formulation of herbicides and pesticides due to its bioactive properties. Structurally, this compound is characterized by the presence of carbamic acid, chloro and trifluoromethyl groups attached to a phenyl ring, and a phenyl ester group. The chloro and trifluoromethyl groups enhance the reactivity and efficacy of the compound, making it a durable and effective ingredient in pest control applications. Despite its wide usage, care must be taken to handle it with caution owing to its potential implications on human health and the environment."

Upstream product

• 1885-14-9 phenyl chloroformate 
• 320-51-4 4-chloro-3-trifluoromethyl-aniline 

Downstream Products

• 70842-07-8 1-(3-Trifluormethyl-4-chlor-phenyl)-5-imino-4,4-dimethyl-2-imidazolidinon 
• 1129683-83-5 4-[ ({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenol 
• 284461-73-0 sorafenib 
• 1012058-78-4 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-2-pyridinecarboxylic acid 

Relevant articles and documents

Discovery and Mechanism of Action of Small Molecule Inhibitors of Ceramidases**

Sphingolipid metabolism is tightly controlled by enzymes to regulate essential processes in human physiology. The central metabolite is ceramide, a pro-apoptotic lipid catabolized by ceramidase enzymes to produce pro-proliferative sphingosine-1-phosphate. Alkaline ceramidases are transmembrane enzymes that recently attracted attention for drug development in fatty liver diseases. However, due to their hydrophobic nature, no specific small molecule inhibitors have been reported. We present the discovery and mechanism of action of the first drug-like inhibitors of alkaline ceramidase 3 (ACER3). In particular, we chemically engineered novel fluorescent ceramide substrates enabling screening of large compound libraries and characterized enzyme:inhibitor interactions using mass spectrometry and MD simulations. In addition to revealing a new paradigm for inhibition of lipid metabolising enzymes with non-lipidic small molecules, our data lay the ground for targeting ACER3 in drug discovery efforts.

Design, synthesis, and biological evaluation of sorafenib derivatives containing indole (ketone) semicarbazide analogs as antitumor agents

A series of new sorafenib derivatives was designed and synthesized. The antiproliferative activity of the synthesized compounds against human lung cancer cell (A549), human pancreatic cancer cell (PC-3), human leukemia cell (K562), and human hepatoma cell (SMMC-7721) was evaluated by MTT assay. The results revealed that several compounds displayed more significant antitumor activities than commercial anticancer agent sorafenib against SMMC-7721. In addition, compounds 7a, 7g, 7l, 7m, and 7p represented obvious growth inhibition with IC50 values of 1-9 μM against four cancer cell lines, demonstrating more predominant activities against cancer cells as compared to sorafenib. Furthermore, some structure-activity relationships have also been established. Compounds containing indole and benzene ring substituted by halogen showed better activity than sorafenib. Wound healing assay suggested that cells would be targeted on their migratory capacity by 7g, potentially affecting the migration activity of these tumors. The effects of A549 and PC-3 cell apoptosis induced by compound 7g were significantly increased compared with sorafenib. Importantly, the result of western blot assay showed that 7g inhibited cell growth by suppressing the activity of EGFR, especially the expression of p-EGFR (Tyr1068).

Medicinal preparation for treating intestinal cancer

The invention discloses a medicinal preparation for treating intestinal cancer. According to the medicinal preparation for treating the intestinal cancer, 4-[4-({[4-CI-3(trichloromethyl)phenyl]carbamyl}amidogen)-3,5-difluorobenzoxy]-N-picoline-2-formamide is adopted as a new active pharmaceutical ingredient, medical auxiliary materials comprise a filling agent, a disintegrating agent, a bonding agent and a lubricating agent. The medicinal preparation is prepared into tablets by adopting a simple pelleting way, significant effects are shown in treatment of a colorectal cancer disease, disintegrating and dissolving of similar medication are relieved, the bioavailability of medication is improved, and the safety is improved.